PTO/SB/81(06-03)

OIPE Under the Paperwork Reduction Act of 1995, no persons are require	U.S. Patent and Trade	mark Office; U.S. DEPARTMENT OF COMMERC ation unless it displays a valid OMB control numbe
	Application Number	10/626,406
APR 1 9 2004 4	Filing Date	July 24, 2003
(D): Mark 1.0 200. 12		

THE PROPERTY OF **POWER OF ATTORNEY** and **CORRESPONDENCE ADDRESS** INDICATION FORM

Application Number	10/626,406
Filing Date	July 24, 2003
First Named Inventor	Blaise Lippa
Title	ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS
Art Unit	Not Assigned
Examiner Name	Not Assigned
Attorney Docket Number	PC25168A

I hereby appoint:						
Practitioners at Custo	mer Number 23	3913				
OR	<u> </u>					
Practitioners named b	elow:					
	Name	Registration Number				
	Water .					
	nt(s) to prosecute the application identifits Patent and Trademark Office connected					
Please recognize or change	the correspondence address for the abo	ove-identified application to:				
The above-mentioned OR	Customer Number.					
The address associate	The address associated with Customer Number OR					
Firm or Individual Name						
Address						
Address						
City		State Zip				
Country						
Telephone		Fax				
I am the:						
Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record						
Name	Blaise Lippa					
Signature	Man I					
Date	1-26-2004					
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
*Total of forms are su	bmitted.					

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81(06-03)

Approved for use through 11/30/2005. OMB 0651-0035

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

10/626 406

Not Assigned

~ ,		10.020,100
nu મુ	Filing Date	July 24, 2003
POWER OF ATTORNEY	First Named Inventor	Blaise Lippa
and	Title	ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS
CORRESPONDENCE ADDRESS	Art Unit	Not Assigned

The same

☐ *Total of ______

forms are submitted.

INDICATION FORM

Application Number

Examiner Name

Attorney Docket Number PC25168A I hereby appoint: Practitioners at Customer Number 23913 Practitioners named below: Name Registration Number as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith. Please recognize or change the correspondence address for the above-identified application to: The above-mentioned Customer Number. OR The address associated with Customer Number OR Firm or Individual Name Address Address City State Zip Country Fax Telephone I am the: Applicant/Inventor. \bowtie Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96). SIGNATURE of Applicant or Assignee of Record Name Tricia Ann Kwan Signature 24 2004 NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Approved for use through 11/30/2005. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

10/626,406

PC25168A

POWER OF ATTORNEY and	Filing Date	July 24, 2003		
	First Named Inventor	Blaise Lippa		
	Title	ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS		
CORRESPONDENCE ADDRESS	Art Unit	Not Assigned		
INDICATION FORM	Examiner Name	Not Assigned		

Application Number

Attorney Docket Number

I hereb	by appoint:						
\boxtimes	Practitioners at Custor	mer Number	23913				
	OR						
	Practitioners named be	elow:					
		Name		Regis	tration Number]	
						_	
						J	
as my busin	y/our attorney(s) or age ess in the United States	nt(s) to prosecute the app s Patent and Trademark (olication identified about their connected their	ove, and to tran rewith.	sact all		
Pleas	se recognize or change	the correspondence addr	ress for the above-ide	entified applicat	ion to:		
	The above-mentioned	Customer Number.					
OR							
	The address associate	ed with Customer Number	r				
OR							
	Firm or Individual Name						
Addr	ess						
Addr	ess						
City		- 12	Stat	е	. Zip		
Cour	itry						
Telep	phone		Fax				
I am th	e:						
\boxtimes	Applicant/Inventor.					,	
	Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record							
Nam	e	Joel Morris					
Sign	ature	foll no	-				
Date			12004				
NOTE: S forms if r	signatures of all the inve more than one signature	entors or assignees of rec e is required, see below*.	ord of the entire inter	rest or their rep	resentative(s) are required.	Submit multiple	
□ *Tota	of forms are sul	bmitted.					

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/81(06-03)
Approved for use through 11/30/2005. OMB 0651-0035
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

	Application Number	10/626,406				
(S)	Filing Date	July 24, 2003				
19 2004 POWER OF ATTORNEY	First Named Inventor	Blaise Lippa				
1 <i>A</i> / and	Title	ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS				
RRESPONDENCE ADDRESS INDICATION FORM	Art Unit	Not Assigned				
INDICATION FORW	Examiner Name	Not Assigned				
	Attorney Docket Number	PC25168A				
I hereby appoint:						
Practitioners at Customer Number OR 23913						
Practitioners named below:						
Name	Registr	ration Number				
Warne	Registi	attor Number				
as my/our attorney(s) or agent(s) to prosecute the application business in the United States Patent and Trademark Office or	n identified above, and to trans connected therewith.	act all				
Please recognize or change the correspondence address for	the above-identified application	on to:				
The above-mentioned Customer Number.						
OR						
The address associated with Customer Number OR						
Firm or Individual Name						
Address	- 117.1					
Address	· · · · · · · · · · · · · · · · · · ·					
City	State	Zip				
Country						
Telephone	Fax					
I am the:						
Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).						
SIGNATURE of Applicant or Assignee of Record						
Name Susan D. LaGreca						
Signature Diano, La Dieca						
Date 1/26/04						
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.						
□ *Total of forms are submitted						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/81(06-03) Approved for use through 11/30/2005. OMB 0651-0035 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

10/626,406

PC25168A

1 .	ו אחת ש	Application Number	10/020,406
Le API	(APR 1 9 2004 H	Filing Date	July 24, 2003
E	POWER OF ATTORNEY	First Named Inventor	Blaise Lippa
. Ve	PADEMARY and	Title	ISOTHIAZOLE DERIVATIVES USEFUL AS ANTICANCER AGENTS
	CORRESPONDENCE ADDRESS	Art Unit	Not Assigned
INDICATION FORM	Examiner Name	Not Assigned	

Application Number

Attorney Docket Number

I hereb	y appoint:	ı						
\boxtimes	Practitioners at Custor	Customer Number 23913						
	OR							
	Practitioners named be	elow:						
		Name			Registra	tion Num	ber	
					·	· · · · · ·	, i, .	
as my busin	as my/our attorney(s) or agent(s) to prosecute the application identified above, and to transact all business in the United States Patent and Trademark Office connected therewith.							
Pleas	se recognize or change	the correspondence addr	ess for the abo	ove-identifi	ed application	to:		
	The above-mentioned	Customer Number.						
OR								
	The address associate	ed with Customer Number						
OR			7 . 4%					
	Firm or Individual Name							
Addr	ess							
Addr	ess							
City				State		Zip		
Cour	itry							
Telep	phone			Fax	7			
I am th	e:							
\boxtimes	Applicant/Inventor.							
	Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTO/SB/96).							
SIGNATURE of Applicant or Assignee of Record								
Nam	Name Matthew David Wessel							
Sign	Signature OWWWW Daum OWWWW							
	Date 1/7:/7004							
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below*.								
□ *Tota	l of forms are su	bmitted.						

This collection of information is required by 37 CFR 1.31 and 1.33. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 3 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.